Cadrenal Therapeutics, Inc. Common Stock(CVKD)Earnings, Financials & Key Ratios
CVKD•NASDAQ
$6.17
$13M mkt cap·Price updated May 6, 2026
AboutCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Show more
- Revenue$0
- EBITDA-$11M-43.6%
- Net Income-$11M-27.5%
- EPS (Diluted)-8.73+9.3%
- ROE-140.78%+82.0%
CVKD Key Insights
Cadrenal Therapeutics, Inc. Common Stock (CVKD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Shares diluted 40.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CVKD Price & Volume
Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock price & volume — 10-year historical chart
Loading chart...
CVKD Growth Metrics
Cadrenal Therapeutics, Inc. Common Stock (CVKD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-89.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.01%
Return on Capital
10 Years-179.4%
5 Years-179.4%
3 Years-179.4%
Last Year-144.87%
CVKD Peer Comparison
Cadrenal Therapeutics, Inc. Common Stock (CVKD) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 TCRX | 162.39M | 1.25 | -1.25 | 266.65% | -15.24% | -91.94% | 0.76 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 BMRN | 10.5B | 54.60 | 30.33 | 12.87% | 8.29% | 4.41% | 0.11 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 CRVS | 1.15B | 15.45 | -29.15 | -23.29% | 0.02 |
Compare CVKD vs Peers
Cadrenal Therapeutics, Inc. Common Stock (CVKD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CVKD Income Statement
Cadrenal Therapeutics, Inc. Common Stock (CVKD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 1.27K | 0 | 0 | 5.92K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | -1.27K▲ 0% | 0▲ 100.0% | 0▲ 0% | -5.92K▲ 0% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | 100% | - | - |
| Operating Expenses | 2.7M | 7.63M | 10.96M | 14.67M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 2.31M | 3.55M | 6.75M | 9.7M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 392.86K | 4.08M | 4.21M | 4.97M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 1.98K | 1.88K | 1.21K |
| Operating Income | -2.7M▲ 0% | -7.63M▼ 182.5% | -10.96M▼ 43.6% | -14.67M▲ 0% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -182.53% | -43.6% | - |
| EBITDA | -2.7M | -7.63M | -10.96M | -14.67M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -182.59% | -43.61% | -84.64% |
| D&A (Non-Cash Add-back) | 1.27K | 1.98K | 1.88K | 6.73K |
| EBIT | -6.61M | -8.34M | -10.65M | -14.45M |
| Net Interest Income | -107.11K | 231.99K | 309.25K | 288.86K |
| Interest Income | - | 249.09K | 309.25K | 288.86K |
| Interest Expense | 107.11K | 17.1K | 0 | 0 |
| Other Income/Expense | -4.01M | -724.24K | 309.25K | 288.86K |
| Pretax Income | -6.71M▲ 0% | -8.36M▼ 24.5% | -10.65M▼ 27.5% | -14.39M▲ 0% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -6.71M▲ 0% | -8.36M▼ 24.5% | -10.65M▼ 27.5% | -14.39M▲ 0% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -24.47% | -27.45% | -89.08% |
| Net Income (Continuing) | -6.71M | -8.36M | -10.65M | -14.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.66▲ 0% | -9.63▼ 11.2% | -8.73▲ 9.3% | -7.04▲ 0% |
| EPS Growth % | - | -11.2% | 9.35% | -10.01% |
| EPS (Basic) | -8.66 | -9.63 | -8.73 | - |
| Diluted Shares Outstanding | 775.64K | 868.18K | 1.22M | 2.04M |
| Basic Shares Outstanding | 775.64K | 868.18K | 1.22M | 2.04M |
| Dividend Payout Ratio | - | - | - | - |
CVKD Balance Sheet
Cadrenal Therapeutics, Inc. Common Stock (CVKD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 727.6K | 8.49M | 10.11M | 4.08M |
| Cash & Short-Term Investments | 32.59K | 8.4M | 10.02M | 3.86M |
| Cash Only | 32.59K | 8.4M | 10.02M | 3.86M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 38.15K | 12.79K |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 672.29K | 0 | 14.45K | 206.85K |
| Total Non-Current Assets | 50.58K | 27.08K | 10.74K | 7.9K |
| Property, Plant & Equipment | 44.59K | 23.29K | 6.94K | 5.73K |
| Fixed Asset Turnover | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -526.01K | 3.79K | 3.79K | 11.92K |
| Total Assets | 778.17K▲ 0% | 8.52M▲ 994.8% | 10.12M▲ 18.8% | 4.09M▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | 994.77% | 18.83% | 28.58% |
| Total Current Liabilities | 1.33M | 826.88K | 2.68M | 1.35M |
| Accounts Payable | 404.9K | 167.32K | 1.5M | 614.13K |
| Days Payables Outstanding | 116.74K | - | - | 66.16K |
| Short-Term Debt | 43.73K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 605.29K | 596.13K | 1.18M | 738.55K |
| Current Ratio | 0.55x | 10.27x | 3.77x | 3.77x |
| Quick Ratio | 0.55x | 10.27x | 3.77x | 3.77x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 4.99M | 0 | 0 | 0 |
| Long-Term Debt | 553.34K | 0 | 0 | 0 |
| Capital Lease Obligations | 21.35K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.42M | 0 | 0 | 0 |
| Total Liabilities | 6.33M | 826.88K | 2.68M | 1.35M |
| Total Debt | 640.71K | 21.35K | 0 | 0 |
| Net Debt | 608.12K | -8.38M | -10.02M | -3.86M |
| Debt / Equity | - | 0.00x | - | 0.00x |
| Debt / EBITDA | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | 0.26x |
| Interest Coverage | -25.22x | -446.34x | - | - |
| Total Equity | -5.55M▲ 0% | 7.69M▲ 238.6% | 7.44M▼ 3.3% | 2.73M▲ 0% |
| Equity Growth % | - | 238.57% | -3.29% | -16.73% |
| Book Value per Share | -7.16 | 8.86 | 6.10 | 1.34 |
| Total Shareholders' Equity | -5.55M | 7.69M | 7.44M | 2.73M |
| Common Stock | 8.19K | 13.02K | 1.78K | 2.06K |
| Retained Earnings | -6.71M | -15.07M | -25.72M | -35.92M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
CVKD Cash Flow Statement
Cadrenal Therapeutics, Inc. Common Stock (CVKD) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -1.2M | -3.53M | -7.36M | -7.36M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -193.03% | -108.41% | -415.96% |
| Net Income | -6.71M | -8.36M | -10.65M | -14.39M |
| Depreciation & Amortization | 1.27K | 1.98K | 1.88K | 6.73K |
| Stock-Based Compensation | 0 | 710.38K | 1.42M | 2.38M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.9M | 3.97M | -352 | -35 |
| Working Capital Changes | 607.74K | 144.31K | 1.87M | 178.54K |
| Change in Receivables | 0 | 0 | 0 | 25.36K |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 404.9K | -237.58K | 1.34M | 117.3K |
| Cash from Investing | -2.28K | -3.25K | -6.54K | -11.64K |
| Capital Expenditures | 0 | -3.25K | -6.54K | -11.64K |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.24M | 11.9M | 8.98M | 11.33M |
| Debt Issued (Net) | 0 | -250K | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 3.65M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 250K | 3.84M | 3.77M |
| Net Change in Cash | 32.59K▲ 0% | 8.37M▲ 25586.4% | 1.62M▼ 80.7% | -503.82K▲ 0% |
| Free Cash Flow | -1.2M▲ 0% | -3.53M▼ 193.3% | -7.36M▼ 108.4% | -11.83M▲ 0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -193.3% | -108.4% | -88.91% |
| FCF per Share | -1.55 | -4.07 | -6.04 | -6.04 |
| FCF Conversion (FCF/Net Income) | 0.18x | 0.42x | 0.69x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
CVKD Key Ratios
Cadrenal Therapeutics, Inc. Common Stock (CVKD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | -780.59% | -140.78% | -279.52% |
| Return on Invested Capital (ROIC) | - | - | 710.25% |
| Debt / Equity | 0.00x | - | 0.00x |
| Interest Coverage | -446.34x | - | - |
| FCF Conversion | 0.42x | 0.69x | 0.82x |
CVKD Frequently Asked Questions
Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cadrenal Therapeutics, Inc. Common Stock (CVKD) grew revenue by 0.0% over the past year. Growth has been modest.
Cadrenal Therapeutics, Inc. Common Stock (CVKD) reported a net loss of $14.4M for fiscal year 2024.
Dividend & Returns
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a return on equity (ROE) of -140.8%. Negative ROE indicates the company is unprofitable.
Cadrenal Therapeutics, Inc. Common Stock (CVKD) had negative free cash flow of $11.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More CVKD
Cadrenal Therapeutics, Inc. Common Stock (CVKD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates